PTJ
ARCT icon

Paul Tudor Jones’s Arcturus Therapeutics ARCT Stock Holding History

Paul Tudor Jones’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,711
Closed -$273K – 2363
2021
Q3 		$273K Buy
+5,711
New +$256K ﹤0.01% 2109
2020
Q3 		– Sell
-4,346
Closed -$203K – 1275
2020
Q2 		$203K Buy
+4,346
New +$150K 0.01% 1023

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's ARCT Position: Q4 2021 in Review

Paul Tudor Jones sold out of Arcturus Therapeutics (ARCT) in Q4 2021, closing a stake of 5,711 shares — an estimated $273K sold.

Paul Tudor Jones first reported a position in ARCT in Q2 2020 and held it in 2 quarters. The position peaked at $273K in Q3 2021. 139 funds tracked by Wall St. Rank hold ARCT as of Q4 2021.

  • Paul Tudor Jones reported no remaining Arcturus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Paul Tudor Jones sold 5,711 Arcturus Therapeutics shares in Q4 2021, an estimated $273K.
  • Paul Tudor Jones first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 2 quarters.
  • Paul Tudor Jones's Arcturus Therapeutics position peaked at $273K in Q3 2021.
  • 139 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2021.

Based on Tudor Investment Corp's 13F filing for Q4 2021, filed 14 Feb 2022.